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ABSTRACT
The methyl-CpG binding domain (MBD) proteins
are key molecules in the interpretation of DNA
methylation signals leading to gene silencing. We
investigated their binding specificity at the constitu-
tively methylated region of a CpG island containing
the bidirectional promoter of the Breast cancer pre-
disposition gene 1, BRCA1, and the Near BRCA1 2
(NBR2) gene. In HeLa cells, quantitative chromatin
immunoprecipitation assays indicated that MBD2 is
associated with the methylated region, while MeCP2
and MBD1 were not detected at this locus. MBD2
depletion ( 90%), mediated by a transgene express-
ing a small interfering RNA (siRNA), did not induce
MeCP2 or MBD1 binding at the methylated area.
Furthermore, the lack of MBD2 at the BRCA1-NBR2
CpG island is associated with an elevated level of
NBR2 transcripts and with a significant reduction
of induced-DNA-hypomethylation response.In MBD2
knockdown cells, transient expression of a Mbd2
cDNA, refractory to siRNA-mediated decay, shifted
down the NBR2 mRNA level to that observed in
unmodified HeLa cells. Variations in MBD2 levels
did not affect BRCA1 expression despite its stimula-
tion by DNA hypomethylation. Collectively, our data
indicate that MBD2 has specific targets and its
presence at these targets is indispensable for gene
repression.
INTRODUCTION
In mammals, DNA methylation at CpG islands located within
regulatory regions is a crucial event in gene silencing. The
various mechanisms leading to methylation-dependent down-
regulation of the transcription remain to be fully determined.
However, the discovery of methyl-CpG binding domain
(MBD) proteins and their interacting partners provides a direct
link between DNA methylation and the establishment of a
repressive chromatin architecture (1). The ﬁve MBD proteins
identiﬁed to date share the functional MBD (2). Four of them,
MBD1, MBD2, MBD3 and MeCP2, are directly involved
in the transcriptional repression of methylated templates in
vertebrates and, with the exception of MBD3, bind methylated
DNA (3).
MeCP2,the foundingmemberoftheMBDfamily,represses
transcription through its interactions with the histone
deacetylase–Sin3 complex and the histone 3 lysine 9
trimethyl-transferase Suv39H1 (4–6). MBD3 is part of the
histone deacetylase and chromatin remodeling Mi2/NuRD
complex, which is targeted to methylated templates in the
MeCP1 complex by MBD2 (7,8). In mouse, an interaction
between the MBD2 and the Sin3 complex has also been
described previously (9). The HDAC complex associated
with MBD1 is not yet identiﬁed (10), but other MBD1 partners
such as histone 3 lysine 9 dimethyl transferase SETDB1 and
the chromatin assembly protein 1 have been characterized
previously (11,12).
In cell lines, MBD1, MBD2 and MeCP2 transiently repress
the expression of genes driven by either strong or weak
promoters (13), suggesting some functional redundancies
between these proteins. Moreover, both the MBD1 and the
MeCP2 proteins are associated, in vivo, with the differentially
methylatedregionof themouseimprinted U2af1-rs1gene (14)
and, in cancer cell lines, some methylated CpG islands are
bound by multiple MBD proteins (15). Since many cell and
tissue types express multiple MBD proteins, these data suggest
that other members of the family might compensate the
absence of a speciﬁc MBD. However, functional speciﬁcities
have been observed. In human, MeCP2 mutations are the
cause of the RETT syndrome (RTT), a neurological disorder
associated with motor function impairment that represents one
of the most common causes of mental retardation in females
(16). In mouse, loss of Mecp2 leads to phenotypes that
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indicating a speciﬁc function of MeCP2 in the maturation
of central nervous system. Mbd1
 /  mice also show
neuronal maturation deﬁcits associated with hippocampal
functions (19). Therefore, the involvement of these proteins
in different pathways of the central nervous system argues
against a functional redundancy between Mecp2 and Mbd1.
In addition, mice lacking Mbd2 do not exhibit speciﬁc pheno-
type except a maternal behavior deﬁcit (20).
Although no global misexpression of endogenous methy-
lated genes has been detected in the ﬁrst studies, candidate
gene approaches have identiﬁed some speciﬁc target genes.
In mouse and rat, Mecp2 is directly involved in a
depolarization-controlled repression of the brain derived
neurotrophic factor gene in neurons (21,22), and that of
the imprinted DLX5 gene driven at a distance by Mecp2
has also been shown previously (23). Speciﬁc repression is
not restricted to MeCP2. In mouse, loss of Mbd1 induces small
but signiﬁcant increase in the expression of the endogenous
virus, IAP, associated with chromosome instability in cultured
neuron cells (19). Mbd2
 /  mice exhibit a disordered helper
T cells differentiation owing to ectopic expression of the
IL4 gene (24).
A comparative study in human cancer cell lines using
a chromatin immunoprecipitation (ChIP) assay combined
with a CpG island microarray also suggests some speciﬁcities,
since some cancer-associated hypermethylated genes are
bound by multiple MBD proteins while others are associated
with a single MBD protein (15). Furthermore, in interphase
MCF7 cells, the distribution of MeCP2 does not parallel that
of methylated cytosine and heterochromatin, and a select-
ive binding of MeCP2 to some repetitive elements has also
been observed previously (25). The mechanisms driving
the MBD binding are not yet fully determined. The relative
abundance of the MBD proteins might be an important para-
meter, since it was suggested that there are more methyl-CpGs
in the genome than MBD protein molecules (1), and whether
MBD1, MBD2 and MeCP2 are randomly associated with sites
or segregate owing to other constraints is not yet known.
To address this question, we investigated in HeLa cells, the
MBD proteins binding pattern at a CpG island located in the
50 end of the Breast cancer predisposition gene 1 (BRCA1).
BRCA1lies head to head with the Near BRCA1 2gene (NBR2)
(26). Experiments of site-directed deletions led to the identi-
ﬁcation of a bidirectional promoter that is embedded within a
large CpG island (13). This CpG island contains a region
that is constitutively methylated in all human cell lines and
tissues, except gametes and preimplantation embryos (27–29).
Therefore, this model represents an interesting tool for inves-
tigating MBD proteins binding speciﬁcity and their effects on
transcription at a naturally methylated CpG island.
MATERIALS AND METHODS
Cell culture
Cervix cancer cell line (HeLa) was obtained from ATCC
(Rockville, MD) and grown in minimum essential medium
(Eagle; Sigma, L’isle d’Abeau, France) supplemented with
10%fetalcalfserum.Cellsweregrownat37 Cinahumidiﬁed
5% CO2 atmosphere.
5-Aza-20-deoxycytidine treatments
For 5-aza-20-deoxycytidine (5-aza-dC; Sigma) treatments, cell
lines were seeded at low density (3–4 · 10
5 cells/100 mm
dish) 16 hbefore treatment with a ﬁnal concentration of 10 mM
5-aza-dC. The medium was changed after 24 h drug addition
and every subsequent day. RNAs were isolated after 72 h.
Cell transfections
pCMV-MeCP2-HA (kindly provided by Dr A. Bird),
pRev-MBD2 (modiﬁed from pCMV-MBD2, kindly provided
by Dr A. Bird) and pGL3 basic (Promega, Lyon, France)
were transfected using the Exgen500 transfection reagent,
according to the manufacturer’s instructions (Euromedex,
Mundolsheim, France). Cells were collected 48 h after trans-
fection. Transfection efﬁciency was tested using a CMV-lacZ
vector and b-galactosidase activity was observed in >90% of
the cells.
Quantification of nucleic acids
Nucleic acids were quantiﬁed by densitometry using the
Fluorimeter Fluors and the Quantity One software (BioRad,
Ivry, France), either from agarose gel containing 1 mg/ml
ethidium bromide or dots mixed with an equal volume of a
200-fold diluted solution of RiboGreen (Molecular Probes,
Interchim, Montlu¸ con, France).
RNA extraction and quantitative RT–PCR
Total RNA was extracted from cell lines with the RNeasy kit
(Qiagen, Courtaboeuf, France) and treated with DNase I using
the DNA-free kit (Ambion Inc., Cambridgeshire, UK). After
extraction, the integrity of total RNA was examined on a 1.2%
agarose gel containing 1 mg/ml ethidium bromide and quan-
tiﬁed. cDNA fragment of NBR2 (from position +146 to +604
from the transcription start site) was ampliﬁed by RT–PCR
using forward 50-GAGGTCTCCAGTTTCGGTAA-30 and
reverse 50-GAACCAAGGTGAAGGACCAA-30. After clon-
ing the PCR product into a pGEM-T easy vector (Promega),
a 109 bp long deletion was performed within the NBR2 cDNA
using the restriction endonuclease MaeIII (Roche, Meylan,
France). The competitor RNA was synthesized using the
Sp6 RNA polymerase according to the manufacturer’s instruc-
tions (Promega). After DNase I digestion (Ambion Inc.) and
RNeasy puriﬁcation (Qiagen), this competitor RNA was quan-
tiﬁed by densitometry and then diluted in the presence of yeast
tRNA as a carrier (40 ng/ml; Ambion). For BRCA1 and MBD2
quantitative RT–PCR, previously designed competitors were
used (30,31).
Equal amounts of total RNA samples (0.6 mg for NBR2,
0.3 mg for BRCA1 and 0.1 mg for MBD2) were coampliﬁed
with increasing amounts of competitor RNAs in a ﬁnal volume
of 50 ml using the One Step RT–PCR kit, Q solution for NBR2
(Qiagen) and 0.6 mM of each primers. After a 30 min incuba-
tion at 50 C, RT was inactivated by heating at 95 C for
15 min. The PCR ampliﬁcation was then accomplished in a
thermocycler under the following conditions: 35 cycles, 30 s
denaturation at 94 C, 1 min annealing at 62 C for NBR2 and
MBD2,6 4  C for BRCA1 and 1 min 30 s extension at 72 C. In
addition, control experiments for each competitor RNA were
performed by omitting the RT to ensure that the signal was the
result of RNA and not DNA ampliﬁcation. PCR products were
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normalized signals corresponding to the target mRNA and
the competitor were plotted against the initial number of
competitor molecules added to the test tubes. The abscissa
of the intersection of the curves represents an estimation of
the equivalence point between the initial amount of the com-
petitor molecules and the number of copies of the mRNA
assayed (32).
Protein extraction and western blot analysis
Forty micrograms of whole cell lysates were separated by
electrophoresis through SDS–10% polyacrylamide gels and
analyzed by western blot (31). For the detection of the
MBD proteins, rabbit polyclonal antibodies against MBD2
(kindly provided by Dr P. Wade) or MeCP2 (Upstate Biotech-
nology, Lake Placid, NY) and mouse monoclonal antibody
against MBD1 (Abgent, San Diego, CA), were diluted
1/2000. The secondary anti-rabbit-HRP or anti-mouse-HRP
conjugate antibodies were diluted 1/5000. The immunocom-
plexes were detected using the ECL system (Amersham,
Saclay, France).
Quantitative chromatin immunoprecipitation
Cells were washed and scraped off the culture dishes in
phosphate-buffered saline, and nuclei were prepared in ice-
cold hypotonic buffer (10 mM Tris–HCl, pH 7.4, 10 mM NaCl
and 5 mM MgCl2). Each step was performed on ice and in
the presence of a mixture of protease inhibitors (Complete
 ;
Roche). After centrifugation, cells were lyzed in the hypotonic
buffer containing 0.1% NP-40. Nuclei were harvested by cen-
trifugation at 2000 r.p.m. (700 g) and were washed in the
same buffer. Nuclear proteins were then cross-linked to
DNA by an incubation with 1% formaldehyde for 10 min
at room temperature and then for 40 min at +4 C. Cross-
linking was stopped by adding 125 mM glycine for 5 min.
After centrifugation, the pellets were washed in the hypotonic
buffer and resuspended in 1–2 ml of SDS lysis buffer (1%
SDS, 10 mM EDTA and 50 mM Tris–HCl, pH 8). Nucleo-
proteincomplexesweresonicated to reduce the lengthof DNA
fragments to 300–600 bp. Insoluble material was removed and
the supernatant was collected. Thirty microliters of this frac-
tion was preserved as an input control and the rest was diluted
1:10 in ChIP dilution buffer (ChIP assay Kit; Upstate Biotech-
nology). The chromatin solution was precleared for 1 h by
incubation with 80 ml of salmon sperm DNA–protein A–
agarose beads (Upstate Biotechnology). The soluble fraction
was collected and 15 ml of monoclonal anti-MBD1 (Abgent),
polyclonal anti-MBD1 (Abcam, Cambridge, UK), anti-MBD2
(kindly provided by Dr P. Wade), anti-MeCP2 (Upstate) and
anti-mouse IgG (Dakocytomation, Trappes, France) antibod-
ies were added and incubated overnight. Then, for ChIP
monoclonal antibodies, 1 mg of rabbit polyclonal anti-
mouse antibody (Dakocytomation) was added and incubated
for 1 h. After immunoprecipitation, immune complexes were
collected by adding 60 ml of salmon sperm DNA–protein
A–agarose beads for 1 h. The supernatant corresponding
to the unbound fraction was collected. After washing (accord-
ing to the manufacturer’s instructions), complexes were
eluted from the beads in 1% SDS and 0.1 M NaHCO3. This
fraction corresponds to the bound (anti-MBD) or the
non-MBD-speciﬁc antibodies (anti-mouse IgG) fractions.
Cross-links were reversed by heating samples at 65 Ci n
200 mM NaCl. DNA was recovered by proteinase K digestion,
phenol extraction and ethanol precipitation. Finally, DNA
samples from the input, unbound, non-MBD-speciﬁc antibody
and bound fractions were quantiﬁed.
Quantitative PCR ampliﬁcation was performed using a
competitor DNA. DNA fragment of the BRCA1-NBR2 CpG
island (from position  1244 to  1004 from the BRCA1
transcription start site, fragment A) was ampliﬁed by PCR
using forward 50-GCTTTTCGCCCACTCGGTCC-30 and
reverse 50-CAGAGCTGGCAGCGGACGGT-30. After clon-
ing the PCR product into a pGEM-T easy vector (Promega),
a single cut within the island fragment was performed using
AccIII and an insertion of a 43 bp chemically synthesized
duplex-oligonucleotide was accomplished using T4 DNA
ligase (Roche). After cloning and puriﬁcation (Plasmid
Maxi Kit; Qiagen), this competitor vector was quantiﬁed.
Equal amounts (2 ng) of total DNA samples from the input,
unbound and bound fractions were coampliﬁed with increas-
ing amounts of competitor plasmid in a ﬁnal volume of 100 ml
using the HotStar Taq polymerase kit (Qiagen) and 0.4 mMo f
each primer. The PCR ampliﬁcation was accomplished after
activationoftheTaqpolymerase(15minat95 Cand35cycles
in a thermocycler under the following conditions: 30 s dena-
turation at 94 C, 1 min annealing at 63 C and 1 min 30 s
extension at 72 C). PCR products were analyzed on a 2%
agarose gel containing 1 mg/ml ethidium bromide and were
quantiﬁed by densitometry as described. Then, the normalized
signals corresponding to the BRCA1 CpG island fragment
and the competitor were plotted against the initial quantity
of competitor molecules added to the test tubes. The abscissa
of the intersection of the curves represents an estimation of the
equivalence point between the initial amount of the competitor
and the quantity of the BRCA1-NBR2 CpG island fragment in
each sample (Supplementary Figure 8s).
We also analyzed three other regions of the methylated
BRCA1-NBR2 CpG island (B, C and D fragments) by perform-
ing a semi-quantitative PCR. We ampliﬁed equal amounts
of total DNA samples (0.5 ng) from the input, unbound
and bound fractions, using forward 50-AAGGGCTCCTC-
CAGCACGGC-30 and reverse 50-TTCTGAGGGACCGA-
GTGGGC-30 for the B fragment (from positions  1364 to
 1218 from the BRCA1 transcription start site); forward
50-TTCAAGCGGGGTGCAGGCGG-30 and reverse 50-CCC-
TCTCTGGGCTGGCCGAA-30 for the C fragment (from
positions  1389 to  1637); forward 50-CTGGTGCATA-
TAAAATCCTCAGGC-30 and reverse 50-GCACAGGG-
CAAGGCTCAGGA-30 for the D fragment (from positions
 1653 to  1928).
As a control, we ampliﬁed an unmethylated region includ-
ing the promoter and the exon 1of the BRCA1 gene (‘promoter
fragment’ from position  56 bp to +263 bp) using forward
50-TAGCCCTTGGGTTCCGTG-30 and reverse 50-TCACAA-
CGCCTTACGCCTC-30.
PCR was accomplished in a ﬁnal volume of 100 ml using the
HotStar Taq polymerase kit (Qiagen) and 0.4 mM of each
primer, as described previously, under the following condi-
tions: 30 s denaturation at 94 C, 1 min annealing at 64 C for
the fragment B, 66 C for the fragments C and D or at 60 C
for the BRCA1 promoter, and 1 min 30 s extension at 72 C.
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Then, the signals corresponding to the BRCA1-NBR2 CpG
island fragment in the input, unbound and bound fractions
were compared.
Stable knockdown of MBD2 by short interfering RNA
and transient reversion
HeLa cells stably expressing small interfering RNA (siRNA)
were established as described previously (33). Brieﬂy, the
pSUPERMBD2 plasmid was generated by cloning the 19 nt
sequence 50-GGAGGAAGTGATCCGAAAA-30 (beginning
575 nt from the translation start site in the mouse MBD2
mRNA), separated by a spacer from its reverse complement
as a BglII/HindIII fragment (synthesized at Proligo, Paris,
France) into the pSUPER vector. This vector directs synthesis
of RNA from the polymerase III-H1-RNA promoter that is
processed in the cell to siRNA. One microgram of pSU-
PERMBD2 was cotransfected with 0.1 mgof a plasmidencoding
a geneticin resistance gene into HeLa cells by using Lipofec-
tamine 2000 (Invitrogen, Cergy Pontoise, France). Cells were
selected using 1 mg/ml G418 (Roche) for 15 days. Clones were
picked and expanded for an additional 20 days and were ana-
lyzed for MBD2 mRNA and protein levels as described
previously.
Transient reversion of RNA interference (RNAi) was
performed by transfecting HeLa clones with a pRev-MBD2
vector in which Mbd2 cDNA sequence was modiﬁed at the
siRNA-target site. Despite ﬁve point mutations (50-GGAAGA
GGTCATTCGCAAA-30, mutated nucleotides are underlined)
and also according to the genetic code, the new cDNA
sequence encodes a functional Mbd2 protein. This vector
was generated by digesting the pCMV-MBD2 vector (kindly
providedby Dr A.Bird) within the Mbd2cDNA sequence with
KspI(Roche)andAccIII(Promega)endonucleases. This KspI/
AccIII fragment was gel-puriﬁed (MinElute gel puriﬁcation
Kit;Qiagen) and digested by ApaI and AccI (Roche). A117 bp
double-stranded oligonucleotide (Eurogentec, Seraing,
Belgium), containing the ﬁve silent point mutations, was intro-
ducedintoApaI/AccIsitetoreplacetheinitial117bpfragment.
After cloning and sequencing (Bioﬁdal, Vaulx-en-Velin,
France), plasmids exhibiting the expected sequence were
selected. The transcription of the mutated form of Mbd2
cDNA allows this mRNA to bypass siRNA-mediated
decay. HeLa and MBD2 knockdown clones were transfected
with the resulting vector. Finally, MBD2 protein expression
was assessed after cellular proteins extraction and western
blotting.
Sodium bisulfite modification
The sodium bisulﬁte modiﬁcation method, followed by
the endonuclease restriction of PCR products, was used to
determine the CpG methylation pattern. Sodium bisulﬁte
converts unmethylated cytosines to uracils whereas the
methylated cytosines remain unmodiﬁed. In the resultant
modiﬁed DNA, uracils are replicated as thymines during
PCR ampliﬁcation (34).
DNA was extracted from cell lines with the QiaAmp DNA
Mini Kit (Qiagen). After extraction, the integrity of total
DNA was examined on a 1.2% agarose gel and quantiﬁed
by densitometry. The sodium bisulﬁte reaction was carried
out as described previously (28). DNA was ampliﬁed using
strand-speciﬁc primers designed to amplify a 304 bp region
(methylated region,  1246 to  942 bp from the BRCA1
transcription start site) and a 250 bp region (unmethylated
region,  592 to  343 bp from the BRCA1 transcription
start site) in the CpG island of the BRCA1 gene. The ﬁrst
round of PCR ampliﬁcation was accomplished in 100 ml
using the HotStar Taq DNA polymerase Kit (Qiagen) and
0.4 mM of the primers (methylated region: forward 50-TTT-
TGTTTTGTGTAGGGCGGTT-30 and reverse 50-CCTTAA-
CGTCCATTCTAACCGT-30; unmethylated region: forward
50-GTTTATAATTGTTGATAAGTATAAG-30 and reverse
50-CCCACTCTTTCCGCCCTAAT-30) after 15 min at 95 C
for Taq polymerase activation and 35 cycles (30 s denaturation
at 94 C, 1 min annealing at 55 C for the methylated region
or at 56 C for the unmethylated region, and 1 min 30 s exten-
sion at 72 C). An aliquot of the ﬁrst ampliﬁcation of the
methylated region was reampliﬁed with internal primers
(forward 50-TGAGAATTTAAGTGGGGTGT-30 and reverse
50AACCCTTCAACCCACCACTAC-30) with the same con-
ditions. PCR products were then analyzed by digestion with
the restrictionenzymes,CfoI(Roche)andHphI(NENBiolabs,
Saint Quentin Yvelines, France). Digestion products were
analyzed on a 2% agarose gel containing 1 mg/ml ethidium
bromide.
RESULTS
MBD2 binds to the methylated region of a CpG island
flanking the bidirectional BRCA1-NBR2 promoter
A large CpG island, 2.8 kb in length, lying from nt  1810 to
+974 from the BRCA1 transcription start site (Figure 1)
exhibits several features, suggesting that it might be a target
for MBD proteins. Indeed, this CpG island is unmethylated
in gametes, but regionally methylated (position  2000 to
  1000) in all tissues and cell lines so far analyzed
(27–29), and nuclease protection assays indicate that this
methylated region is embedded in a condensed chromatin
structure in breast cell lines (29) and in HeLa cells (data
not shown).
Quantitative ChIP assays were performed using antibodies
directed against MBD1, MBD2 and MeCP2. The analyzed
region (nt  1244 to  1004; Figure 1, ‘A’ segment) is located
close to, but does not overlap with, the repetitive element
LTR12c (nt  3125 to  1276), which is part of the CpG island
(Figure 1). Data obtained from at least three independent ChIP
assays for each antibody are shownin Figure 2A. The fractions
immunoprecipitated with a non-MBD protein speciﬁc anti-
body (anti-mouse IgG) did not contain enough DNA for
PCR assay, indicating an efﬁcient preclearing step.
When antibodies against MBD2 are used, the amount of
BRCA1-NBR2 CpG island per ng of total DNA in immuno-
precipitated fraction (Figure 2A, ‘bound’) is higher ( 5-fold)
than in input or non-retained fractions (Figure 2A, ‘input’
and ‘unbound’). Therefore, these data indicate that the
BRCA1-NBR2 CpG island is speciﬁcally immunoprecipitated
by the anti-MBD2 antibodies. In contrast, when antibodies
against MeCP2 or MBD1 are used, the immunoprecipitated
fraction is depleted in BRCA1-NBR2 CpG island, since the
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input and the unbound fractions (Figure 2A).
A dose-dependent ampliﬁcation of the ‘B’ region (nt  1364
to  1218) was performed on each fraction obtained from the
ChIP procedure (Figure 2B). As observed at the segment lying
from position  1244 to  1004, enrichment in BRCA1-NBR2
CpG island DNA in the bound fraction is only observed
when the chromatin is immunoprecipitated with anti-MBD2
antibodies, while ChIPs with anti-MeCP2 or anti-MBD1
antibodies lead to a depletion of this DNA in the bound
Figure 1. TheBRCA1-NBR2locus.TheBRCA1geneislocatedheadtoheadwiththeNBR2geneandthetwogenesareseparatedbya bidirectionnalpromoter(25).
Transcription start sites of both genes are arrowed in black. Black box, BRCA1 and NBR2 exons. The locus includes a CpG island of 2784 bp in length (%G+C, 57;
ObsCpG/ExpCpG, 0.65; CpGProD software, http://pbil.univ-lyon1.fr). M+, constitutively methylated region of the CpG island (28); light gray box, LTR12c
retroelement; dark gray box, AluY sequence (Repeat Masker software, version 2002). Black lines represent the positions of the fragments amplified byA ,
competitive PCR; B, C, D and ‘promoter’, semi-quantitative PCR, after ChIP. Positions are indicated from the BRCA1 transcription start site.
Figure 2. MBD2 associates the methylated region of the BRCA1 CpG island in HeLa cells. (A) Amounts of immunoprecipitated BRCA1 island (fragment A,
see Figure 1) measured by competitive PCR (error bars, SD from, at least, three independent experiments). Cross-linked chromatin was immunoprecipitated using
rabbitpolyclonalanti-MBD2,anti-MeCP2,anti-MBD1ormonoclonalmouseanti-MBD1antibodies.PurifiedDNAfromtheinput,unboundorboundfractionswas
quantified and quantitative PCR analysis was accomplished. Then, the intensity of the bands corresponding to the PCR products was plotted against the initial
numberofcompetitormoleculesasdescribedinSupplementaryData,Figure8s.Blackbox,amountofBRCA1islandfragmentsperngoftheinputDNA.Openbox,
amountofBRCA1islandfragmentsperngoftheunboundDNA.Graybox,amountofBRCA1islandfragmentsperngoftheboundDNA.(B)Threeotherregionsof
theBRCA1CpGislandwereanalyzedbyChIP.Theseregions,fragmentsB,CandD(Figure1),arelocatedupstreamthefirstregionamplifiedbycompetitivePCR.
After immunoprecipitation, purified DNA from the different fractions was quantified and 0.5 ng of this DNA was amplified. The intensities of the bands
corresponding to the PCR products amplified from the input, unbound and bound fractions are shown. (C) Representative experiment of PCR amplification of
anunmethylatedregionincludingthepromoterandtheexon1oftheBRCA1gene(‘promoterfragment’fromposition 56to+263bpfromtheBRCA1transcription
start site) on MBD2-ChIP fractions.
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the repeated LTR12c element was further investigated by
performing ChIP assays at the ‘C’ region (nt  1389 to  1637)
and ‘D’ region (nt  1653 to  1928). A signiﬁcant enrichment
of these fragments in the chromatin fraction immunoprecipi-
tated by antibodies against MBD2 was observed (Figure 2B).
We also ampliﬁed an unmethylated region containing the
promoter and the exon 1 of the BRCA1 gene (from position
 56 to +263 bp from the BRCA1 transcription start site).
As expected, enrichment in BRCA1-NBR2 CpG island was
not observed in the chromatin fraction immunoprecipitated
with anti-MBD2 antibodies (Figure 2C), since the ampliﬁed
segment is unmethylated in HeLa cells (28). Taken together,
these data strongly suggest that the methylated region of
the BRCA1-NBR2 CpG island is only bound by MBD2 in
HeLa cells and that MBD2 binds only to the methylated
region.
Depletion of MBD2 is not compensated by the binding
of MeCP2 or MBD1 at the methylated region of
BRCA1-NBR2 CpG island
HeLa cells contain  20 times more MBD2 than MeCP2
transcripts (30). In addition, it has been shown that some
methylated DNA regions are bound by multiple MBD pro-
teins (15). Taken together, these data suggest that the speciﬁc
binding of MBD2 to the BRCA1-NBR2 CpG island might be a
consequence of the relative concentrations of the MBD pro-
teins in HeLa cells. To address this issue, MBD proteins bind-
ing patterns at this CpG island were investigated in HeLa cells
depleted inMBD2.Stable clones, expressinga siRNA targeted
to MBD2 transcripts (MBD2a and b isoforms), were con-
structed by stable transfection of pSUPER vector (33) con-
taining a MBD2 speciﬁc insert.
In several HeLa clones, quantitative competitive RT–PCR
assays indicated a constitutive reduction of 89–96% in MBD2
mRNA level (Figure 3A, MBD2 KD clones). Western blot
analysis also showed a dramatic decrease in MBD2 proteins
in these MBD2 KD clones carrying the pSuper-MBD2 trans-
gene (Figure 3B). In addition, persistent suppression of MBD2
expression is conserved after many passages since efﬁcient
MBD2 knockdown is still observed after 2 months of continu-
ous culture. Furthermore, the expression of MeCP2 and MBD1
was not affected in MBD2 knockdown clones (KD clones)
when compared with the wild-type HeLa cells (data not
shown).
Quantitative ChIP assays from HeLa cells depleted in
MBD2 proteins showed no BRCA1-NBR2 CpG island enrich-
ment in the bound fraction when chromatin is immunoprecipi-
tated with anti-MBD2 antibodies (Figure 4A). Furthermore, as
previously observed in HeLa cells, the immunoprecipitated
fractions are depleted in the methylated island when anti-
MeCP2oranti-MBD1wereused(Figure4A).Thesameresults
were obtained when a different antibody, anti-MBD1, was
used (data not shown). In addition, a positive immunoprecipi-
tation of MeCP2-bound chromatin has been obtained in
another set of experiments (Figure 7A and B), and in KD
cells additional ChIP control experiments indicated that
MBD1 proteins were associated with juxtacentromeric
sequences Sat2 (data not shown). Thus, in MBD2-depleted
HeLa cells, the methylated region (nt  1244 to  1004) of
BRCA1-NBR2 CpG island is not bound by these other two
MBD proteins. This observation was extended to the adjacent
methylated sequences (nt  1364 to  1218) using a semi-
quantitative approach (Figure 4B). Taken together, these
data indicate that the methylated region of the BRCA1 island
remains free from MeCP2 or MBD1 in MBD2-depleted HeLa
cells, suggesting that MBD2 binding is speciﬁc.
TranscriptionalrepressionoftheBRCA1-NBR2locusby
MBD2
The bidirectional promoter, driving both BRCA1 and NBR2
expression, is relatively far ( 1 kb) from the methylated
domain of the CpG island. However, in human cell lines,
chemically induced demethylation stimulates BRCA1 gene
expression and in vitro methylated expression vectors carrying
this CpG island is repressed when transiently transfected
into human cell lines (28). Since NBR2 and BRCA1 share
the same promoter region (Figure 1), we tested a potential
role of DNA methylation in the expression of the NBR2
gene. In HeLa cells, demethylation was induced by
5-aza-dC treatments. NBR2 transcripts were then quantiﬁed
usinga competitive RT–PCR method (arepresentativeassay is
shown in Figure 5A). As described previously (28), 5-aza-dC
treatment of HeLa cells elevated BRCA1 expression by
1.8-fold and an overexpression of NBR2 (3.1-fold) was also
observed (Figure 5B).
These data raised the question whether MBD2 is a
methylation-dependent repressor of the BRCA1-NBR2
Figure 3. MBD2 mRNA and protein quantification in HeLa cells expressing
stable siRNA (MBD2 knockdown cells). (A) Quantification of MBD2 mRNA
by competitive RT–PCR assay in wild-type HeLa and three clones of MBD2
knockdown cells (a, b and c) performed from 0.1 mg of total RNA mixed with
increasing amount of competitor MBD2 RNA. The intensity of the bands
corresponding to the PCR products was plotted against the initial number of
competitormoleculesin orderto estimatethe amountofMBD2mRNApresent
in1mgofeachsample.(B)ImmunoblotanalysisofMBD2proteinsinHeLaand
knockdown cell lines. MBD2 proteins were probed using a rabbit polyclonal
antibody. Then, the same membrane was probed using a mouse b-tubulin
antibody as a loading control.
4248 Nucleic Acids Research, 2005, Vol. 33, No. 13Figure 4. MeCP2 and MBD1 do not compensate for MBD2 depletion at the BRCA1-NBR2 CpG island in MBD2 knockdown HeLa cells. (A) Amounts of
immunoprecipitated BRCA1island(fragmentA, Figure 1)measured by competitivePCR (error bars, SD from, at least, three independent experiments).Blackbox,
amount of BRCA1 island fragments per ng of the input DNA. Open box, amount of BRCA1 island fragments per ng of the unbound DNA. Gray box, amount of
BRCA1 island fragments per ng of the bound DNA. (B) Representative examples of BRCA1 semi-quantitative PCR (fragment B, Figure 1) on MBDs-ChIP assays
(as described in Figure 2B).
Figure 5. Effects of 5-aza-dC on the expression of BRCA1 and NBR2 in HeLa and MBD2 knockdown cells. (A) Quantitative competitive RT–PCR assay of NBR2
mRNAswasperformedfrom0.6mgoftotalRNAmixedwithincreasingamountofNBR2competitorRNA.Amountsofcompetitormolecules:lane1,5 · 10
4;lane2,
10
5;lane3,5 · 10
5;lane4,10
6;lane5,5 · 10
6.TheRT–PCRproductswereanalyzedona 2%agarosegelcontainingethidiumbromide.Theintensityofthebands
corresponding to the PCR products was plotted against the initial number of competitor molecules. The diagrams of the intensity values are represented below the
gels.Blackbox,349bpbandcompetitorNBR2RNA;openbox,458bpbandendogenousNBR2RNA.(B)NBR2andBRCA1transcriptsinHeLacellsandMBD2KD
cells treated oruntreatedwith 10mM5-aza-dCfor72 h.QuantitativeRT–PCRanalyseswere performedfrom0.6 mg oftotal RNAmixed withincreasingamountof
competitorNBR2RNAorfrom0.3mgoftotalRNAmixedwithincreasingamountofcompetitorBRCA1RNA(32).Averagevaluesobtainedfromfourindependent
experiments (error bar, SD) are shown. Control: untreated cells.
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of NBR2 expression by 1.7-fold is observed when compared
with wild-type HeLa cells (Figure 5B). In addition, in MBD2
KD clones, 5-aza-dC treatments (Figure 5B) had a lower
effect (1.6-fold) on NBR2 expression than in wild-type cells
(3.1-fold). Since both cell types exhibit the same amount of
NBR2 transcripts after 5-aza-dC treatments (Figure 5B), these
data suggest that MBD2 is an important factor in the NBR2
methylation-dependent control.
However, the same amounts of BRCA1 transcripts were
found in MBD2 KD clones and in wild-type HeLa cells
(Figure 5B). In addition, BRCA1 response to 5-aza-dC treat-
ment is not modiﬁed by MBD2 depletion (Figure 5B), indi-
cating that BRCA1 expression is independent of the MBD2
binding. Furthermore, control experiments indicated that
the methylation pattern of BRCA1-NBR2 CpG island was not
modiﬁed in MBD2 KD cells when compared with the
wild-type HeLa cells (Supplementary Data, Figure 9s). Taken
together, these data suggest a speciﬁc methylation-dependent
repression of NBR2 by MBD2.
Mbd2 expression rescues the reduction of NBR2
transcript in MBD2 knockdown clones
Functional control of the speciﬁc repression of NBR2 by
MBD2 has been performed by expressing the MBD2 target-
cDNA in a form that is refractory to siRNA-mediated decay.
Five silent point mutations of the third-codon within the
targeted region were introduced into a mouse Mbd2 cDNA
and the resulting expression vector (pRev-MBD2) was tran-
siently expressed in MBD2 KD clones after transfection.
Western blot analysis of HeLa and MBD2 KD clones indicated
that Mbd2 proteins were efﬁciently expressed from the
pRev-MBD2 expression vector (Figure 6A).
In wild-type HeLa cells, the level of BRCA1 and NBR2
transcripts was not affected by the Mbd2 overexpression
due to the pRev-MBD2 vector (Figure 6B). Also, the
pCMV-MBD2 expression vector containing a non-mutated
mouse Mbd2 cDNA did not alter BRCA1 and NBR2 transcrip-
tion in HeLa cells (data not shown). Therefore, the amount of
MBD2 is not a limiting factor in the transcriptional repres-
sion of the BRCA1-NBR2 locus, in HeLa cells. In contrast, in
MBD2 KD cells, pRev-MBD2 expression induced a 28–45%
decrease in NBR2 expression (Figure 6B) and transfected
MBD2 KD cells exhibited an NBR2 mRNA level equivalent
to the level observed in wild-type HeLa cells. No statistically
signiﬁcant decrease in BRCA1 mRNA level was observed in
these transfected MBD2 KD cells (Figure 6B). These data
conﬁrm that, at the BRCA1-NBR2 locus, MBD2 speciﬁcally
represses the NBR2 gene.
Specificity of transcriptional repression by MBD2
Taken together, these data indicate that, in HeLa cells, under
physiological concentrations, MBD2 binds to the BRCA1-
NBR2 CpG island and the absence of this protein is not com-
pensated by the binding of other MBD proteins. However,
experiments have suggested that exogenous BRCA1 might
be repressed by the overexpression of Mecp2 (28). We
have, therefore, investigated the ability of the exogenous
Mecp2 to repress the transcription of the endogenous locus.
Mecp2 was overexpressed in HeLa and MBD2 KD cells by
transient transfection of the pCMV-MeCP2-Ha vector.
Immunoblotsindicated ahighexpression ofMecp2after trans-
fection in both cell types (Supplementary Data, Figure 10s).
Quantitative ChIP assays, from transfected MBD2 KD cells,
showed a slight ( 1.7-fold) but statistically signiﬁcant enrich-
ment in the A segment of BRCA1-NBR2 CpG island (Figure 1,
‘A’ segment) in the chromatin fraction immunoprecipitated by
antibodies against MeCP2 (Figure 7A). Mecp2 binding was
further conﬁrmed by a semi-quantitative ChIP in the adjacent
region (Figure 7B). This Mecp2 binding is associated with a
decrease (17–26%) in NBR2 transcripts (Figure 7C), when
compared toMBD2 KDcells transfectedwith an emptyvector.
In addition, in HeLa cells, overexpression of Mecp2 did not
modify NBR2 transcription, as observed after pRev-MBD2
transfections (Figure 7C). BRCA1 mRNA amounts remain
unchanged in both wild-type and MBD2 KD HeLa cells
expressing MeCP2 at a high level (Figure 7C). Thus, in
MBD2 depleted cells, elevated level of exogenous Mecp2
leads to Mecp2 binding at the BRCA1-NBR2 locus and to a
partial repression of NBR2.
DISCUSSION
Transient transfection of in vitro methylated expression vec-
tors has clearly demonstrated that members of the methyl-CpG
binding protein family, MBD1, MBD2 and MeCP2, are
directly involved in the methylation-dependent repression of
Figure 6. MBD2 transfection experiments in HeLa and MBD2 knockdown
cells.(A)ImmunoblotanalysisofMBD2proteinsinHeLaandMBD2KDcells
transfected with an MBD2 vector expressing a transcript resistant to RNAi
(pRev-MBD2 vector). HeLa and MBD2 KD cells were transfected with the
pRev-MBD2 vector or with an empty pGL3 basic vector (pGL3). MBD2
proteins, from whole cell extract prepared 48 h after transfection, were probed
using a rabbit polyclonal antibody. (B) Quantitative RT–PCR analysis of
BRCA1 and NBR2 transcripts was performed (as described in Figure 5) from
HeLa and MBD2 KD cells transfected with the pRev-MBD2 or an empty
vector (pGL3). The ratio between the amounts of the transcripts in pRev-
MBD2-transfectedcells andpGL3-transfectedcells wasthencalculated.Mean
values obtained from at least four independent transfection experiments are
shown [*P ¼ 0.0049 (<0.05), t-test].
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to a prominent effect on cerebral function (17–19), suggesting
a speciﬁc dependence of these tissues on the control medi-
ated by MBD proteins. Alternatively, functional redundancy
between MBD proteins may be more important in other tis-
sues. In line with this hypothesis, global gene overexpression
was not observed in mice lacking a particular MBD protein
(17–20). Nevertheless, further studies indicated that gene-
speciﬁc dysregulation in non-cerebral tissues are associated
with the loss of MBD proteins (21,22,24). Analysis of the
chromatin proteins also raises the question of the redundancy
between these proteins.
Our analysis, in the HeLa cell line, of a CpG island at the
BRCA1-NBR2 locus indicates that the methylated part of this
CpG island is bound by MBD2 while MeCP2 and MBD1 are
not detected in this region. Furthermore, western blot analysis,
using antibodies directed against MeCP2 and MBD1 produced
a signal at the expected size (15),  85 and  70 kDa, respec-
tively, indicating that both proteins are expressed in this cell
line (data not shown). Thus, the lack of detection of these two
proteins at the methylated region of the BRCA1-NBR2 CpG
island is not due to their absence. In addition, the depletion
in BRCA1-NBR2 CpG island in the chromatin fractions
immunoprecipitated by the anti-MeCP2 and MBD1 antibodies
also indicates that these two proteins are linked to other chro-
matindomains inHeLa cells. Therefore, themethylated partof
this CpG island seems to be speciﬁcally associated with
MBD2 in our cellular model. Although all the MBD proteins
are ubiquitously expressed in somatic tissues, variations in
their expression levels, depending on the cell type and the
differentiation state, have been observed previously (35).
For example, in mouse brain, Mecp2 and Mbd1 are highly
expressed when compared with Mbd2 (2), while MBD2 tran-
scripts are 20-fold more abundant than MeCP2 mRNA in
breast tissues (30), suggesting that the relative MBD protein
concentrations might be involved in the phenotypes associated
with their experimental depletions. Therefore, their relative
concentrations might be associated with a prominent binding
of MBD2 to some methylated DNA segments. However, in
these cells, the strong targeted-depletion of MBD2 proteins,
induced by RNAi, does not induce the binding of other MBD
proteins at the methylated region of the BRCA1-NBR2 CpG
island. Thus, these data suggest that this sequence is a pref-
erential target for MBD2.
Among the mechanisms potentially involved in the prefer-
ential binding of MBD2, differences in afﬁnity for methylated
DNA might be an important component, since it was shown
that murine Mbd2b exhibits a higher afﬁnity than Mecp2 for
methylated oligonucleotides (36). Although this possibility
cannot be excluded, it should be noted that, in MBD2 knock-
down HeLa clones, MBD2 proteins were nearly undetectable
and the amount of the transcripts was reduced by 92% on the
average, while MeCP2 and MBD1 protein levels remained
unchanged (data not shown). In addition, hypermethylated
CpG islands are associated with MeCP2 in several cell
lines and tissues expressing all MBD proteins (14,15,37,38)
and when overexpressed in HeLa cells depleted in MBD2
proteins, Mecp2 binds to the BRCA1-NBR2 CpG island.
Taken together, these data suggest that corepressors of tran-
scription leading to a non-permissive chromatin environment
may be, in vivo, of importance for the speciﬁc recruitment
of MBD2, or alternatively for the exclusion of MeCP2 and
MBD1 at the BRCA1-NBR2 locus. The possible presence of a
recently described MBD2 partner, the MIZF protein (39),
has also been investigated, since the methylated region of the
BRCA1-NBR2 CpG island contains a consensus binding site
for this protein at position  960 bp. However, we failed to
detect MIZF at this locus by ChIP (data not shown).
In human cell lines, while chemically induced hypomethy-
lation was associated with the activation of both BRCA1 and
NBR2, transcriptional repression mediated by MBD2 seemed
to be gene speciﬁc, since MBD2 knockdown elevated only
NBR2 transcription, in HeLa cells. In addition, this phenotype
wasrescuedbyexogenousMbd2,indicatingthatthiseffectisa
speciﬁc consequence of the MBD2 knockdown. Furthermore,
Figure 7. MeCP2 transfection experiments in HeLa and MBD2 knockdown
cells. (A) Quantitative MeCP2-ChIP assays in MBD2 KD cells transfected
with the pCMV-MeCP2-HA vector. After immunoprecipitation of cross-
linked chromatin with an anti- MeCP2 antibody, competitive PCR analysis
(fragment A, Figure 1) was performed (as described in Figure 2). Average
values obtained from two independent MeCP2-ChIP assays are shown. (B)A
representative example of a BRCA1 semi-quantitative PCR (fragment B,
Figure 1) performed on these ChIP assays. See Supplementary Results for
immunoblot controls (Supplementary Figure 10s). (C) BRCA1 and NBR2
mRNAquantificationinHeLaandMBD2KDcellstransfectedwithanMeCP2
vector.FourindependenttransfectionexperimentsofHeLaandMBD2KDcells
with the pCMV-MeCP2-HA vector or an empty pGL3 basic vector (pGL3),
RNA extraction and quantitative RT–PCR analysis were performed. Average
values are presented on this graph [*P ¼ 0.018 (< 0.05), t-test].
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involved in BRCA1 expression, since the expression of exoge-
nous Mbd2 did not modify the amounts of BRCA1 transcripts
in both wild-type HeLa cells and MBD2 KD cells. Moreover,
the response of NBR2 to DNA hypomethylation was reduced
by a factor of  2 in MBD2-depleted HeLa cells, while BRCA1
response was not affected by the MBD2-siRNA. Although
MBD2 depletion does not completely abolish the effect of
5-aza-dC, the consistent reduction of 5-aza-dC-response in
MBD2-depleted HeLa cells conﬁrms that MBD2 signiﬁcantly
contributes to the methylation-dependent NBR2 repression.
In the human genome, BRCA1 lies head to head with the
NBR2 gene (40). The transcription start site of BRCA1 is
separated from the NBR2 gene by a 218 bp bidirectional pro-
moter (40,41). This region is embedded within a large CpG
island (13) and the methylated part of this region corresponds
to a nuclease resistant chromatin structure in human breast cell
lines(29) and inHeLa cells. Hence,this region is located at the
30 end of the NBR2 transcription start site and at the 50 end of
BRCA1 (Figure 1). The speciﬁcity of MBD2 towards NBR2
transcription from the bidirectional BRCA1-NBR2 promoter,
suggests that the methylation-dependent repression of NBR2
and BRCA1 is mediated by different mechanisms.
The analysis of the 50 region of the endothelin receptor B
gene in human cell lines shows that extensive methylation
closely downstream of the initiation site does not abolish
gene expression (42). However, studies using plasmid and
episomal vectors (43–45) and patch methylation techniques
indicate that methylation downstream of a promoter can
decrease transcription levels, suggesting that this epigenetic
mark may also affect the elongation rate. Therefore, the
reduced expression of NBR2 mediated by MBD2 might be
dependent on such mechanisms. In line with this hypothesis,
BRCA1 expression is not affected by MBD2 binding to the
methylated region of the CpG island upstream its promoter.
Nevertheless, inhibition of DNA methylation stimulates
BRCA1 expression, suggesting that its repression might be
associated with the binding of different MBD proteins to
some other methylated DNA segments. Alternatively, DNA
methylation may have a direct effect on the binding of regu-
latory factors since it was suggested that the  1582 to  202
region of the 50 end of BRCA1 contains several weak regu-
latory sites (both enhancers and repressors) with additive
effects (40) and a putative cAMP-responsive element binding
transcription factor binding site has been mapped in the
BRCA1 promoter (46).
MBD2 belongs to a family of methylation-dependent tran-
scriptional repressor and its presence in aberrantly methylated
genes has been observed in human cancer cell lines (47–49).
However, a direct relationship between MBD2 binding and
gene repression has been established only for a few genes.
In mouse, it had been shown that Gata-3 and Mbd2 act in
competition for the regulation of Il4 gene transcription in
T-helper cells (49). Evidences for a contribution of MBD2
in silencing the aberrantly methylated pi-class glutathione
S-transferase (GSTP1) promoter have been obtained, in
the breast cancer cell line MCF7 cells, by MBD2-depletion
mediated by siRNA (48).
Functional domains have been mapped within the MBD
proteins and beside their methyl-CpG binding domain, all
these proteins posses a domain involved in gene repression,
the transcriptional repression domains (TRDs); in contrast
to the MBD, no sequence similarities were found between
the different TRDs (1). Many promoters, including Simian
virus 40, cytomegalovirus and beta-actin promoters (3), are
efﬁciently repressed by tethering the minimal TRD of MeCP2,
MBD1 and MBD2. However, it was shown that the L1
promoter is not repressed by fusion protein containing the
TRD of MBD2, but is silenced by fusion proteins containing
either MeCP2 or MBD1 TRDs (50). The repression of NBR2
by MBD2 does not seem to be speciﬁc of its TRD, since in
MBD2-depleted HeLa cells, exogenous Mecp2 decreased
NBR2 transcription. Similarly, inhibitory effect of exogenous
Mecp2 has already been observed in Mbd2
 /  mice. Indeed,
previous studies have shown that the methylation-dependent
repression of reporter genes is impaired in ﬁbroblast cell lines
from these mice, suggesting that endogenous Mecp2 proteins
do not compensate for the absence of Mbd2 (18). Never-
theless, exogenous Mecp2 restores full repression in the
Mbd2
 /  cells, indicating that the overexpression of Mecp2
can counteract the absence of Mbd2 in this system (18).
Although Mbd2
 /  mice are viable and fertile (20), a reduc-
tion in Mbd2 inhibits the development of intestinal adenomas
in the tumor-prone Apc
Min/+ mouse (51). In human cell lines,
MBD2 antisense inhibitors suppress tumorigenesis in vitro and
invivo,whenthesecellsare implantedinnude mice asamodel
(52). Taken together these data suggest that MBD2 represents
a new target potential in cancer therapy and, therefore, new
insights on MBD2 speciﬁcities are, in this context, of impor-
tance. Collectively, our data indicate that MBD2 speciﬁcally
binds to the BRCA1 island and represses NBR2. In addition,
our results suggest that the relative abundance of MBD is not a
major factor in their targeting to some methylated DNAs.
Furthermore, the cellular model developed in this study
may represent a valuable tool for the identiﬁcation of
MBD2 target genes, which could be valuable for therapeutics
applications.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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